高通量基因检测系统MammaPrint与乳腺癌预后预测

Gene expression profiling to predict the prognosis of breast cancer

化疗是乳腺癌患者术后最重要的辅助治疗手段。由于传统的临床病理指标不能准确预测患者复发风险,因此不能准确筛选出哪些患者需要化疗、哪些患者不需要化疗。高通量基因检测系统MammaPrint已被证实可较准确预测相当一部分乳腺癌患者复发风险,因而可用于指导个体化治疗。本文就MammaPrint的临床应用及研究现状作一综述。

Chemotherapy is the most important postsurgery adjuvant therapy in the treatment of breast cancer.A major challenge is the selection of patients to determine who do require chemotherapy and who do not.The clinicopathological criteria is far from accurate for prediction of prognosis,causing a proportion of overtreatment.Using high throughput microarray analysis.MammaPrint which was identified can accurately divide patients into good and bad outcomes.The aim of this paper was to elaborate the research progress and its clinical utility for better understanding it.